- Home
- HP vs AXSM Comparison
HP vs AXSM Comparison
Compare HP & AXSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HP
- AXSM
- Stock Information
- Founded
- HP 1920
- AXSM 2012
- Country
- HP United States
- AXSM United States
- Employees
- HP N/A
- AXSM N/A
- Industry
- HP Oil & Gas Production
- AXSM Biotechnology: Pharmaceutical Preparations
- Sector
- HP Energy
- AXSM Health Care
- Exchange
- HP Nasdaq
- AXSM Nasdaq
- Market Cap
- HP 3.6B
- AXSM 4.2B
- IPO Year
- HP N/A
- AXSM 2015
- Fundamental
- Price
- HP $36.39
- AXSM $96.18
- Analyst Decision
- HP Hold
- AXSM Strong Buy
- Analyst Count
- HP 9
- AXSM 13
- Target Price
- HP $39.50
- AXSM $130.69
- AVG Volume (30 Days)
- HP 1.2M
- AXSM 965.3K
- Earning Date
- HP 02-05-2025
- AXSM 02-18-2025
- Dividend Yield
- HP 0.69%
- AXSM N/A
- EPS Growth
- HP N/A
- AXSM N/A
- EPS
- HP 3.43
- AXSM N/A
- Revenue
- HP $2,756,607,000.00
- AXSM $338,457,000.00
- Revenue This Year
- HP $20.69
- AXSM $44.77
- Revenue Next Year
- HP $10.70
- AXSM $67.70
- P/E Ratio
- HP $10.62
- AXSM N/A
- Revenue Growth
- HP N/A
- AXSM 51.47
- 52 Week Low
- HP $29.46
- AXSM $64.11
- 52 Week High
- HP $44.11
- AXSM $105.00
- Technical
- Relative Strength Index (RSI)
- HP 67.52
- AXSM 59.04
- Support Level
- HP $34.80
- AXSM $91.81
- Resistance Level
- HP $37.30
- AXSM $95.36
- Average True Range (ATR)
- HP 1.06
- AXSM 4.95
- MACD
- HP 0.52
- AXSM 1.43
- Stochastic Oscillator
- HP 86.93
- AXSM 89.89
About HP Helmerich & Payne Inc.
Helmerich & Payne maintains one of the largest fleets of land drilling rigs in the US. The company's FlexRig line is the leading choice to drill horizontal wells for production of US tight oil and gas. H&P is present in nearly every major US shale play and has a small but growing presence internationally.
About AXSM Axsome Therapeutics Inc.
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products include AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.